Tóm tắt
Background: Systemic inflammation plays a pivotal role in breast cancer (BC) progression and has been increasingly recognized as an important component associated with tumor aggressiveness. Inflammatory indices derived from routine blood tests, particularly the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR), reflect the balance between tumor-promoting inflammatory responses and host antitumor immune surveillance. Objectives: To evaluate changes in systemic inflammatory markers in BC patients compared with healthy controls and to analyze their associations with TNM stage and immunohistochemical (IHC) subtypes. Methods: A descriptive cross-sectional study was conducted at Hue University Hospital, enrolling 24 newly diagnosed, untreated female BC patients and 24 healthy women. Clinical characteristics, TNM staging, and immunohistochemical (IHC) profiles (ER, PR, HER2, Ki-67) were collected. Patients were classified into early-stage (TNM I–IIA) and late-stage disease (TNM IIB–IV). Based on IHC profiles, tumors were categorized into Luminal A, Luminal B, HER2-positive, and triple-negative breast cancer (TNBC), with Luminal A considered low-risk and non-Luminal A subtypes considered higher-risk. NLR and PLR were calculated from peripheral blood counts and compared between groups, across disease stages, and IHC-based risk categories. Results: BC patients exhibited significantly higher NLR and PLR than controls (P < 0.05). Both indices were significantly elevated in BC patients with advanced-stage (IIB–IV) compared with early-stage (I–IIA). Patients with high-risk IHC subtypes, particularly non-Luminal A tumors, showed significantly higher NLR levels than those with Luminal A tumors. In contrast, conventional tumor markers, including CEA, CA 15-3, and C-reactive protein, did not show statistically significant differences across TNM stages or IHC subtypes. Conclusion: NLR and PLR are closely associated with disease stage and immunohistochemical subtypes in breast cancer. As simple, low-cost, and readily available parameters, these indices may provide complementary information to conventional markers for initial risk stratification and clinical assessment in breast cancer patients.
| Đã xuất bản | 30-04-2026 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Tập 16 Số 02 (2026) | |
| Phân mục | Nghiên cứu | |
| DOI | 10.34071/jmp.2026.2.869 | |
| Từ khóa | Breast cancer, Systemic inflammation, Neutrophil-to-lymphocyte ratio, Platelet-to-lymphocyte ratio, TNM stage, Immunohistochemistry |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2026 Tạp chí Y Dược Huế
Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021 Dec;32(12):1475-1495.
Loibl S, Andre F, Bachelot T, Barrios CH, Bergh J, Burstein HJ, et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159-182.
Sun Y, Guan Y, Yu H, Zhang Y, Tao J, Zhang W, Yao Y. Predictive model using systemic inflammation markers to assess neoadjuvant chemotherapy efficacy in breast cancer. Front Oncol. 2025;15:1552802.
Liu X, Qu JK, Zhang J, Yan Y, Zhao XX, Wang JZ, et al. Prognostic role of pretreatment neutrophil to lymphocyte ratio in breast cancer patients: A meta-analysis. Medicine (Baltimore). 2017 Nov;96(45):e8101.
Zhao Z, Xu H, Ma B, Dong C. Prognostic value of platelet to lymphocyte ratio (PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis. Front Immunol. 2025 Aug 20;16:1658571.
Harborg S, Larsen HB, Elsgaard S, Borgquist S. Metabolic syndrome is associated with breast cancer mortality: A systematic review and meta-analysis. J Intern Med. 2025;297(3):262–275.
Zhang Y, Ge Y, Xu Y, Zhao M. Prognostic value of CA15-3, CA125, CEA in breast cancer patients undergoing chemotherapy. J Med Biochem. 2025;44(7):1466-1477.
Hung DT, Tuoi LT. Study on changes in plasma CA 15-3 levels in breast cancer patients treated with Tamoxifen at K Hospital from 2019 to 2022. J Community Med [Internet]. 2024 Sep 4 [cited 2025 Dec 23];65(5). Available from: https://tapchiyhcd.vn/index.php/yhcd/article/view/1431. Vietnamese.
Hutajulu SH, Astari YK, Ucche M, Kertia N, Subronto YW, Paramita DK, et al. Prognostic significance of C-reactive protein (CRP) and albumin-based biomarker in patients with breast cancer receiving chemotherapy. PeerJ. 2025;13:e19319.
Huang Q, Huang K, Qian J, Yang Y. Platelet-to-lymphocyte ratio as a prognostic biomarker in patients with human epidermal growth factor receptor 2-negative breast cancer undergoing taxane-carboplatin-based neoadjuvant chemotherapy. Ther Adv Med Oncol. 2025;17:17588359251369041.
Nguyen TH, Tran BN, Dao TH. Relationship between peripheral blood cell ratios and chemotherapy outcomes in breast cancer patients at Thai Nguyen Central Hospital. Ho Chi Minh City Medical Journal. 2019;23(3):279-285. Available from: https://tapchiyhoctphcm.vn/upload/2019/23%203%20%20thong%20nhat/279.pdf. Vietnamese.